We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+3.36%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$737M
(+20%)
Cap. Flow
+$736M
Cap. Flow
% of AUM
16.32%
Top 10 Holdings %
Top 10 Hldgs %
19.25%
Holding
501
New
284
Increased
70
Reduced
66
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$99.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$80.7M |
| 3 |
Johnson & Johnson
JNJ
|
+$77.7M |
| 4 |
Electronic Arts
EA
|
+$61.9M |
| 5 |
Danaher
DHR
|
+$60.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$99.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$97.8M |
| 3 |
Medtronic
MDT
|
+$68.7M |
| 4 |
NXP Semiconductors
NXPI
|
+$61.6M |
| 5 |
Lumentum
LITE
|
+$58.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.83% |
| 2 | Technology | 26.25% |
| 3 | Communication Services | 6.68% |
| 4 | Consumer Discretionary | 4.05% |
| 5 | Financials | 2.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Johnson & Johnson
JNJ
$635B
| $171M | 3.8% |
1,042,685
+480,461
| +85% | +$77.7M |
|
2
Amphenol
APH
$188B
| $112M | 2.48% |
3,387,778
+475,378
| +16% | +$15.4M |
|
|
3
Gilead Sciences
GILD
$161B
| $99.7M | 2.21% |
+1,541,893
| New | +$99.4M |
|
|
4
Danaher
DHR
$135B
| $89.5M | 1.98% |
448,436
+296,525
| +195% | +$60.2M |
|
|
5
Regeneron Pharmaceuticals
REGN
$68.8B
| $88M | 1.95% |
185,899
+165,695
| +820% | +$80.7M |
|
6
Fidelity National Information Services
FIS
$21.5B
| $70M | 1.55% |
498,124
-138,404
| -22% | -$18.9M |
|
7
Texas Instruments
TXN
$255B
| $65.4M | 1.45% |
346,093
+28,985
| +9% | +$5.04M |
|
|
8
Electronic Arts
EA
$52.4B
| $60.5M | 1.34% |
+446,767
| New | +$61.9M |
|
9
Zimmer Biomet
ZBH
$17.7B
| $56.1M | 1.25% |
361,194
+279,456
| +342% | +$43.3M |
|
10
NVIDIA
NVDA
$5.01T
| $55.8M | 1.24% |
4,178,160
+1,831,960
| +78% | +$24.6M |
|
11
Intuitive Surgical
ISRG
$121B
| $55.5M | 1.23% |
+225,387
| New | +$56.7M |
|
12
Meta Platforms (Facebook)
META
$1.51T
| $55M | 1.22% |
+186,819
| New | +$50.3M |
|
13
Vishay Intertechnology
VSH
$5.86B
| $51.9M | 1.15% |
2,153,219
-701,953
| -25% | -$16.4M |
|
14
Vor Biopharma
VOR
$1.04B
| $49.7M | 1.1% |
+57,663
| New | +$48.8M |
|
15
Micron Technology
MU
$1.04T
| $49.2M | 1.09% |
557,964
-216,161
| -28% | -$18.3M |
|
16
Advanced Micro Devices
AMD
$851B
| $46.8M | 1.04% |
+596,108
| New | +$51.3M |
|
17
Booking.com
BKNG
$138B
| $46.7M | 1.04% |
+501,100
| New | +$44.5M |
|
18
Qorvo
QRVO
$7.63B
| $46.6M | 1.03% |
255,280
-68,621
| -21% | -$12M |
|
19
Vertex Pharmaceuticals
VRTX
$121B
| $46M | 1.02% |
+214,076
| New | +$47M |
|
20
Global Payments
GPN
$22.1B
| $45.7M | 1.01% |
226,829
-174,759
| -44% | -$34.8M |
|
|
DRNA
21
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $45.4M | 1.01% |
1,777,000
+418,204
| +31% | +$10.7M |
|
22
TG Therapeutics
TGTX
$8.58B
| $44.7M | 0.99% |
926,766
+893,514
| +2,687% | +$42.9M |
|
23
Agios Pharmaceuticals
AGIO
$2.16B
| $42.6M | 0.94% |
+824,097
| New | +$40.8M |
|
|
HZNP
24
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $42M | 0.93% |
456,871
+312,210
| +216% | +$26.3M |
|
25
PagSeguro Digital
PAGS
$2.57B
| $41.8M | 0.93% |
+902,254
| New | +$48.4M |
|
Similar funds
KAS
PAM
TCIIS
Woodline Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Woodline Partners held 501 positions worth $4.51B, up 20% from $3.77B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Woodline Partners deployed $736M of net new capital in Q1 2021, opening 284 new positions and adding to 70 existing holdings. Its largest new stake was Gilead Sciences: 1,541,893 shares worth $99.7M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Amgen, an estimated $99.3M trimmed.
- Woodline Partners's largest Q1 2021 buy was Gilead Sciences: 1,541,893 shares worth $99.7M.
- Woodline Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $80.7M increase.
- Woodline Partners's biggest Q1 2021 reduction was Amgen, cutting an estimated $99.3M.
- Woodline Partners fully exited Alphabet (Google) Class A in Q1 2021, selling an estimated $97.8M.
- Woodline Partners's ten largest holdings make up 19% of its $4.51B portfolio in Q1 2021.
- Woodline Partners opened 284 new positions and closed 74 in Q1 2021.
- Woodline Partners's portfolio value rose 20% quarter-over-quarter to $4.51B.
Based on Woodline Partners's 13F filing for Q1 2021, filed 17 May 2021.